The Short Answer
With early treatment, most patients achieve good symptom control and prevent permanent facial nerve damage; however, Melkersson's syndrome is typically a chronic condition requiring long-term monitoring and occasional medication adjustments [1]. Without treatment, recurrent swelling and nerve inflammation can lead to permanent facial weakness, chronic pain, and permanent tongue changes [1].
The natural history of untreated Melkersson's syndrome shows progressive facial nerve damage: each swelling episode and recurrent inflammation can cause cumulative nerve injury, leading to permanent one-sided facial weakness, chronic facial pain, and permanent fissuring of the tongue [1]. Some patients experience spontaneous remission (symptom resolution without treatment), but this is unpredictable and may take years; waiting for remission risks permanent damage.
With early corticosteroid and immunosuppressive therapy, most patients achieve remission or long-term control: 60–70% of patients on appropriate treatment experience significant reduction in swelling frequency and severity, and facial nerve function stabilizes or improves [1]. The fissured tongue typically persists even after swelling resolves, but it causes no functional harm. Facial nerve strength often recovers fully if treatment starts early.
Long-term management involves regular neurology follow-up (every 3–6 months initially, then annually once stable), periodic MRI to monitor for structural changes, and blood tests if on immunosuppressive agents [1]. Most patients can taper steroids to low maintenance doses or discontinue them entirely after 1–2 years of immunosuppressive therapy. The key is preventing recurrent flares through consistent medication adherence and early recognition of warning signs (facial swelling or weakness returning).